254 related articles for article (PubMed ID: 32103422)
1. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.
Hackeng WM; Schelhaas W; Morsink FHM; Heidsma CM; van Eeden S; Valk GD; Vriens MR; Heaphy CM; Nieveen van Dijkum EJM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Endocr Pathol; 2020 Jun; 31(2):108-118. PubMed ID: 32103422
[TBL] [Abstract][Full Text] [Related]
2. Aggressive versus indolent insulinomas: new clinicopathological insights.
Hackeng WM; Brosens LAA; Dreijerink KMA
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36779771
[TBL] [Abstract][Full Text] [Related]
3. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration.
Hackeng WM; Morsink FHM; Moons LMG; Heaphy CM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
Diagn Cytopathol; 2020 Apr; 48(4):308-315. PubMed ID: 31846235
[TBL] [Abstract][Full Text] [Related]
5. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.
Hackeng WM; van Beek DJ; Kok ASM; van Emst M; Morsink FHM; van Treijen MJC; Borel Rinkes IHM; Dreijerink KMA; Offerhaus GJA; Valk GD; Vriens MR; Brosens LAA
Am J Surg Pathol; 2022 Feb; 46(2):159-168. PubMed ID: 34560682
[TBL] [Abstract][Full Text] [Related]
7. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
8. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
[TBL] [Abstract][Full Text] [Related]
9. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
[TBL] [Abstract][Full Text] [Related]
10. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract][Full Text] [Related]
11. Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics.
Zhang J; Jiang R; Hong X; Wu H; Han X; Wu W
Front Oncol; 2023; 13():1109330. PubMed ID: 37251916
[TBL] [Abstract][Full Text] [Related]
12. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
13. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL
Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal instability predicts metastatic disease in patients with insulinomas.
Jonkers YM; Claessen SM; Perren A; Schmid S; Komminoth P; Verhofstad AA; Hofland LJ; de Krijger RR; Slootweg PJ; Ramaekers FC; Speel EJ
Endocr Relat Cancer; 2005 Jun; 12(2):435-47. PubMed ID: 15947114
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors.
Mastrosimini MG; Manfrin E; Remo A; De Bellis M; Parisi A; Pedron S; Luchini C; Brunelli M; Ammendola S; Bernardoni L; Conti Bellocchi MC; Gabbrielli A; Facciorusso A; Pea A; Landoni L; Scarpa A; Crinò SF
Pancreatology; 2023 Jun; 23(4):429-436. PubMed ID: 37169669
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
19. DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients.
Jonkers YM; Claessen SM; Perren A; Schmitt AM; Hofland LJ; de Herder W; de Krijger RR; Verhofstad AA; Hermus AR; Kummer JA; Skogseid B; Volante M; Voogd AC; Ramaekers FC; Speel EJ
Endocr Relat Cancer; 2007 Sep; 14(3):769-79. PubMed ID: 17914106
[TBL] [Abstract][Full Text] [Related]
20. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
